<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39312552</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2767-3375</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PLOS global public health</Title><ISOAbbreviation>PLOS Glob Public Health</ISOAbbreviation></Journal><ArticleTitle>'Our project, your problem?' A case study of the WHO's mRNA technology transfer programme in South Africa.</ArticleTitle><Pagination><StartPage>e0003173</StartPage><MedlinePgn>e0003173</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0003173</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgph.0003173</ELocationID><Abstract><AbstractText>In June 2021 the World Health Organization (WHO) and the Medicines Patent Pool (MPP) launched an mRNA technology transfer programme. With a South African consortium serving as the hub, the programme aimed to increase vaccine manufacturing capacity in low- and middle-income countries (LMICs) in view of the "vaccine apartheid" that was observed during COVID-19. Following Clarke's "situational analysis," the present study assessed whether the mRNA programme differs from the approach and practices that comprise current biopharmaceutical production. Numerous documentary sources, including legal agreements underpinning the programme, funding agreements, and patent filings, were reviewed. Semi-structured interviews with 35 individuals, ranging from the programme's architects and university scientists to representatives from LMIC vaccine manufacturers taking part in the programme were also conducted. While the mRNA programme may improve the sharing of knowledge, other design features, in particular, weak conditionalities around product affordability, participants' freedom to contract with third parties, and acceptance of market-based competition, are in line with the status quo. Further, WHO and MPP's tight control over the programme evokes the dynamics that are often in play in global health, to the detriment of empowering LMIC-based manufacturers to generate mRNA products in response to local health needs.</AbstractText><CopyrightInformation>Copyright: © 2024 Herder, Benavides. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herder</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5319-6199</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Pharmacology, Dalhousie University, Halifax, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Justice Institute, Schulich School of Law, Dalhousie University, Halifax, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benavides</LastName><ForeName>Ximena</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Program of Ethics, Politics and Economics, Yale University, New Haven, Connecticut, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Information Society Project, Yale Law School, New Haven, Connecticut, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLOS Glob Public Health</MedlineTA><NlmUniqueID>9918283779606676</NlmUniqueID><ISSNLinking>2767-3375</ISSNLinking></MedlineJournalInfo><CoiStatement>We have read the journal’s policy and the authors of this manuscript have the following competing interests: Matthew Herder was a member of the Patented Medicine Prices Review Board (PMPRB), Canada’s national drug pricing regulator, and received honoraria for his public service, June 2018 – February 2023. The PMPRB had no role whatsoever in the design or conduct of this research. Ximena Benavides worked for GAVI - The Vaccine Alliance, COVAX Facility, from May to October of 2021, as a Yale Institute for Global Health fellow.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>22</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39312552</ArticleId><ArticleId IdType="pmc">PMC11419367</ArticleId><ArticleId IdType="doi">10.1371/journal.pgph.0003173</ArticleId><ArticleId IdType="pii">PGPH-D-24-00260</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Massinga Loembé M, Nkengasong JN. COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead. Immunity. 2021. Jul 13;54(7):1353–62. doi: 10.1016/j.immuni.2021.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.017</ArticleId><ArticleId IdType="pmc">PMC8276532</ArticleId><ArticleId IdType="pubmed">34260880</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamey G, Garcia P, Hassan F, Mao W, McDade KK, Pai M, et al.. It is not too late to achieve global covid-19 vaccine equity. BMJ. 2022. Mar 24;376:e070650. doi: 10.1136/bmj-2022-070650</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-070650</ArticleId><ArticleId IdType="pmc">PMC8943596</ArticleId><ArticleId IdType="pubmed">35331982</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown G.
Project Syndicate. 2021 [cited 2021 Jun 19]. Vaccines for All or Vaccine Apartheid? | by Gordon Brown. Available from: https://www.project-syndicate.org/commentary/g7-must-finance-global-covid19-vaccination-drive-by-gordon-brown-2021-06.</Citation></Reference><Reference><Citation>Chadwick C, Friede M, Moen A, Nannei C, Sparrow E. Technology transfer programme for influenza vaccines–Lessons from the past to inform the future. Vaccine. 2022. Aug 5;40(33):4673–5. doi: 10.1016/j.vaccine.2022.06.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.057</ArticleId><ArticleId IdType="pmc">PMC9406834</ArticleId><ArticleId IdType="pubmed">35810059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fidler DP. Influenza Virus Samples, International Law, and Global Health Diplomacy. Emerg Infect Dis. 2008. Jan;14(1):88–94. doi: 10.3201/eid1401.070700</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1401.070700</ArticleId><ArticleId IdType="pmc">PMC2600156</ArticleId><ArticleId IdType="pubmed">18258086</ArticleId></ArticleIdList></Reference><Reference><Citation>Friede M, Palkonyay L, Alfonso C, Pervikov Y, Torelli G, Wood D, et al.. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: Supporting developing country production capacity through technology transfer. Vaccine. 2011. Jul 1;29:A2–7. doi: 10.1016/j.vaccine.2011.02.079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.02.079</ArticleId><ArticleId IdType="pubmed">21684422</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxmen A. South African scientists copy Moderna’s COVID vaccine. Nature. 2022. Feb;602(7897):372–3. doi: 10.1038/d41586-022-00293-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00293-2</ArticleId><ArticleId IdType="pubmed">35115696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kana BD, Arbuthnot P, Botwe BK, Choonara YE, Hassan F, Louzir H, et al.. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa. The Lancet Infectious Diseases. 2023. Aug 1;23(8):e288–300. doi: 10.1016/S1473-3099(22)00878-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00878-7</ArticleId><ArticleId IdType="pubmed">37290473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bump JB, Aniebo I. Colonialism, malaria, and the decolonization of global health. PLOS Global Public Health. 2022. Sep 6;2(9):e0000936. doi: 10.1371/journal.pgph.0000936</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0000936</ArticleId><ArticleId IdType="pmc">PMC10021769</ArticleId><ArticleId IdType="pubmed">36962810</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer P, Kim JY, Kleinman A, Basilico M. Reimagining Global Health: An Introduction. Univ of California Press; 2013. 508 p.</Citation></Reference><Reference><Citation>Lawrence DS, Hirsch LA. Decolonising global health: transnational research partnerships under the spotlight. International Health. 2020. Nov 9;12(6):518–23. doi: 10.1093/inthealth/ihaa073</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/inthealth/ihaa073</ArticleId><ArticleId IdType="pmc">PMC7651076</ArticleId><ArticleId IdType="pubmed">33165557</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy D, Kapilashrami A, Kumar R, Rhule E, Khosla R. Developing an agenda for the decolonization of global health. Bull World Health Organ. 2024. Feb 1;102(2):130–6. doi: 10.2471/BLT.23.289949</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.23.289949</ArticleId><ArticleId IdType="pmc">PMC10835633</ArticleId><ArticleId IdType="pubmed">38313156</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy D, Khosla R. Public health leaders must confront the power imbalances that harm global health. Nat Med. 2023. Jul 7;1–2.</Citation><ArticleIdList><ArticleId IdType="pubmed">37420099</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy D, Roberts S, Daoudi S, Kennedy J. Global health security and the health-security nexus: principles, politics and praxis. BMJ Global Health. 2023. Sep 1;8(9):e013067. doi: 10.1136/bmjgh-2023-013067</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2023-013067</ArticleId><ArticleId IdType="pmc">PMC10537961</ArticleId><ArticleId IdType="pubmed">37748796</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke A. Situational Analysis: Grounded Theory After The Postmodern Turn. SAGE; 2005. 412 p.</Citation></Reference><Reference><Citation>Martin W, Pauly B, MacDonald M. Situational Analysis for Complex Systems: Methodological Development in Public Health Research. AIMS Public Health. 2016;3(1):94–109. doi: 10.3934/publichealth.2016.1.94</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/publichealth.2016.1.94</ArticleId><ArticleId IdType="pmc">PMC5690266</ArticleId><ArticleId IdType="pubmed">29546149</ArticleId></ArticleIdList></Reference><Reference><Citation>Herder M. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency. The Milbank Quarterly. 2019;97(3):820–57. doi: 10.1111/1468-0009.12413</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1468-0009.12413</ArticleId><ArticleId IdType="pmc">PMC6739605</ArticleId><ArticleId IdType="pubmed">31407412</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleeson D, Townsend B, Tenni BF, Phillips T. Global inequities in access to COVID-19 health products and technologies: A political economy analysis. Health &amp; Place. 2023. Sep 1;83:103051. doi: 10.1016/j.healthplace.2023.103051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthplace.2023.103051</ArticleId><ArticleId IdType="pmc">PMC10247888</ArticleId><ArticleId IdType="pubmed">37379732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali SH, Rose JR. The post-colonialist condition, suspicion, and social resistance during the West African Ebola epidemic: The importance of Frantz Fanon for global health. Social Science &amp; Medicine. 2022. Jul 1;305:115066. doi: 10.1016/j.socscimed.2022.115066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2022.115066</ArticleId><ArticleId IdType="pubmed">35636052</ArticleId></ArticleIdList></Reference><Reference><Citation>Abimbola S, Asthana S, Montenegro C, Guinto RR, Jumbam DT, Louskieter L, et al.. Addressing power asymmetries in global health: Imperatives in the wake of the COVID-19 pandemic. PLOS Medicine. 2021. Apr 22;18(4):e1003604. doi: 10.1371/journal.pmed.1003604</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003604</ArticleId><ArticleId IdType="pmc">PMC8101997</ArticleId><ArticleId IdType="pubmed">33886540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kentikelenis A, Rochford C. Power asymmetries in global governance for health: a conceptual framework for analyzing the political-economic determinants of health inequities. Globalization and Health. 2019. Nov 28;15(1):70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6881908</ArticleId><ArticleId IdType="pubmed">31775894</ArticleId></ArticleIdList></Reference><Reference><Citation>MPP. MPP. [cited 2023 Aug 24]. Programme agreements. Available from: https://medicinespatentpool.org/what-we-do/mrna-technology-transfer-programme/agreements.</Citation></Reference><Reference><Citation>MPP. VaxPaL—COVID-19 vaccines patent database MPP [Internet]. 2021.  [cited 2024 Jan 15]. Available from: https://medicinespatentpool.org/what-we-do/vaxpal.</Citation></Reference><Reference><Citation>Kavanagh MM, Singh R. Vaccine politics: Law and inequality in the pandemic response to COVID-19. Global Policy. 2023;14(2):229–46.</Citation></Reference><Reference><Citation>Moon S, Armstrong J, Hutler B, Upshur R, Katz R, Atuire C, et al.. Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability. The Lancet. 2022. Jan 29;399(10323):487–94. doi: 10.1016/S0140-6736(21)02344-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02344-8</ArticleId><ArticleId IdType="pmc">PMC8797025</ArticleId><ArticleId IdType="pubmed">34902308</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bengy Puyvallée A, Storeng KT. COVAX, vaccine donations and the politics of global vaccine inequity. Globalization and Health. 2022. Mar 5;18(1):26. doi: 10.1186/s12992-022-00801-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12992-022-00801-z</ArticleId><ArticleId IdType="pmc">PMC8897760</ArticleId><ArticleId IdType="pubmed">35248116</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeyi OO. Misguided charity: the bane of global health. BMJ Glob Health. 2023. Sep 15;8(9):e013322. doi: 10.1136/bmjgh-2023-013322</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2023-013322</ArticleId><ArticleId IdType="pmc">PMC10510901</ArticleId><ArticleId IdType="pubmed">37714564</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushkaran A, Chattu VK, Narayanan P. A critical analysis of COVAX alliance and corresponding global health governance and policy issues: a scoping review. BMJ Glob Health. 2023. Oct 4;8(10):e012168. doi: 10.1136/bmjgh-2023-012168</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2023-012168</ArticleId><ArticleId IdType="pmc">PMC10551961</ArticleId><ArticleId IdType="pubmed">37793808</ArticleId></ArticleIdList></Reference><Reference><Citation>C-TAP: A concept paper [Internet]. [cited 2024 Jan 8]. Available from: https://www.who.int/publications/m/item/c-tap-a-concept-paper.</Citation></Reference><Reference><Citation>World Health Organization. COVID-19 technology access pool [Internet]. [cited 2023 Nov 21]. Available from: https://www.who.int/initiatives/covid-19-technology-access-pool.</Citation></Reference><Reference><Citation>Neeraj V.
Journal of Public and International Affairs. 2022.  [cited 2024 Jan 8]. Patents, Pandemics, and the Private Sector: The Battle Over Public Health Norms During COVID-19. Available from: https://jpia.princeton.edu/news/patents-pandemics-and-private-sector-battle-over-public-health-norms-during-covid-19.</Citation></Reference><Reference><Citation>Zaitchik A.
How Bill Gates Impeded Global Access to Covid Vaccines.
The New Republic [Internet]. 2021. 
Apr
12 [cited 2021 Aug 17]; Available from: https://newrepublic.com/article/162000/bill-gates-impeded-global-access-covid-vaccines.</Citation></Reference><Reference><Citation>Kapczynski A. Order without Intellectual Property Law: Open Science in Influenza. Cornell Law Review. 2017. Sep 1;102(6):1539–648.</Citation><ArticleIdList><ArticleId IdType="pubmed">29048862</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadwick C, Friede M, Moen A, Nannei C, Sparrow E. Technology transfer programme for influenza vaccines–Lessons from the past to inform the future. Vaccine. 2022. Aug 5;40(33):4673–5. doi: 10.1016/j.vaccine.2022.06.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.057</ArticleId><ArticleId IdType="pmc">PMC9406834</ArticleId><ArticleId IdType="pubmed">35810059</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous. World Health Organization. 2021.  [cited 2023 Dec 20]. Call for expression of interest to: Contribute to the establishment of a COVID-19 mRNA vaccine technology transfer hub. Available from: https://www.who.int/news-room/articles-detail/call-for-expression-of-interest-to-contribute-to-the-establishment-of-a-covid-19-mrna-vaccine-technology-transfer-hub.</Citation></Reference><Reference><Citation>Pan-American Health Organization [Internet]. 2021.  [cited 2024 Jan 8]. PAHO selects centers in Argentina, Brazil to develop COVID-19 mRNA vaccines—PAHO/WHO |
Pan American Health Organization. Available from: https://www.paho.org/en/news/21-9-2021-paho-selects-centers-argentina-brazil-develop-covid-19-mrna-vaccines.</Citation></Reference><Reference><Citation>WHO PDVAC [Internet]. [cited 2023 Nov 28]. 2021 meetings: WHO Product Development for Vaccines Advisory Committee (PDVAC). Available from: https://www.who.int/news-room/events/detail/2021/04/15/default-calendar/pdvac-2021.</Citation></Reference><Reference><Citation>Gore C, Morin S, Røttingen JA, Kieny MP. Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider’s story. BMJ Global Health. 2023. Sep 1;8(9):e012964. doi: 10.1136/bmjgh-2023-012964</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2023-012964</ArticleId><ArticleId IdType="pmc">PMC10496684</ArticleId><ArticleId IdType="pubmed">37669799</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiger S, Gross N. Market Failures and Market Framings: Can a market be transformed from the inside? Organization Studies. 2018. Oct 1;39(10):1357–76.</Citation></Reference><Reference><Citation>Cleary EG, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. PNAS. 2018 Mar 6;115(10):2329–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5878010</ArticleId><ArticleId IdType="pubmed">29440428</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak RK, Avorn J, Kesselheim AS. Public sector financial support for late stage discovery of new drugs in the United States: cohort study. BMJ [Internet]. 2019. 
Oct
23 [cited 2020 Jun 5];367. Available from: http://www.bmj.com/content/367/bmj.l5766. doi: 10.1136/bmj.l5766

</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l5766</ArticleId><ArticleId IdType="pmc">PMC6812612</ArticleId><ArticleId IdType="pubmed">31645328</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The Role of Public-Sector Research in the Discovery of Drugs and Vaccines. N Engl J Med. 2011. Feb 10;364(6):535–41. doi: 10.1056/NEJMsa1008268</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa1008268</ArticleId><ArticleId IdType="pubmed">21306239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee SK, Rohrbaugh ML. NIH inventions translate into drugs and biologics with high public health impact. Nat Biotech. 2014. Jan;32(1):52–8. doi: 10.1038/nbt.2785</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2785</ArticleId><ArticleId IdType="pubmed">24406928</ArticleId></ArticleIdList></Reference><Reference><Citation>Herder M, Graham JE, Gold R. From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine. Journal of Law and the Biosciences [Internet]. 2020. Jul 25 [cited 2021 Nov 2];7(1). Available from: doi: 10.1093/jlb/lsz019</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jlb/lsz019</ArticleId><ArticleId IdType="pmc">PMC8249092</ArticleId><ArticleId IdType="pubmed">34221434</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalani HS, Nagar S, Sarpatwari A, Barenie RE, Avorn J, Rome BN, et al.. US public investment in development of mRNA covid-19 vaccines: retrospective cohort study. BMJ. 2023. Mar 1;380:e073747. doi: 10.1136/bmj-2022-073747</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-073747</ArticleId><ArticleId IdType="pmc">PMC9975718</ArticleId><ArticleId IdType="pubmed">36858453</ArticleId></ArticleIdList></Reference><Reference><Citation>Herder M.
Biopharmaceuticals, Financialization &amp; Nationalism in the Age of COVID-19 [Internet].
Healthy Debate. 2021.  [cited 2021 May 19]. Available from: https://healthydebate.ca/2021/03/topic/biopharmaceuticals-financialization/.</Citation></Reference><Reference><Citation>Mazzucato M, Li HL. A Market Shaping Approach for the Biopharmaceutical Industry: Governing Innovation Towards the Public Interest. Journal of Law, Medicine &amp; Ethics. 2021. ed;49(1):39–49. doi: 10.1017/jme.2021.8</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/jme.2021.8</ArticleId><ArticleId IdType="pubmed">33966657</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzucato M, Rodrik D. Industrial Policy with Conditionalities: A Taxonomy and Sample Cases [Internet]. 2023. 
Oct [cited 2023 Oct 8]. Available from: https://www.ucl.ac.uk/bartlett/public-purpose/publications/2023/oct/industrial-policy-conditionalities-taxonomy-and-sample-cases.</Citation></Reference><Reference><Citation>Eren Vural I, Herder M, Doll A, Graham JE. Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic. International Journal of Health Policy and Management. 2023. Dec 1;12(Issue 1):1–16. doi: 10.34172/ijhpm.2023.6936</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/ijhpm.2023.6936</ArticleId><ArticleId IdType="pmc">PMC10462233</ArticleId><ArticleId IdType="pubmed">37579382</ArticleId></ArticleIdList></Reference><Reference><Citation>MPP. mRNA Funders—MPP [Internet]. 2023.  [cited 2023 Aug 28]. Available from: https://medicinespatentpool.org/what-we-do/mrna-technology-transfer-programme/mrna-funders.</Citation></Reference><Reference><Citation>Tarbet EB, Dorward JT, Day CW, Rashid KA. Vaccine production training to develop the workforce of foreign institutions supported by the BARDA influenza vaccine capacity building program. Vaccine. 2013. Mar 15;31(12):1646–9. doi: 10.1016/j.vaccine.2012.06.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.06.041</ArticleId><ArticleId IdType="pubmed">22749796</ArticleId></ArticleIdList></Reference><Reference><Citation>GAC. Global Affairs Canada ATIP file #A-2022-03880. 2023.</Citation></Reference><Reference><Citation>NIAID’s VRC S.
Africa’s Afrigen Kick Off Vaccine-Sharing Efforts | NIH: National Institute of Allergy and Infectious Diseases [Internet].
2023.  [cited 2023 Aug 17]. Available from: https://www.niaid.nih.gov/news-events/afrigen-blog.</Citation></Reference><Reference><Citation>Public Citizen [Internet]. 2022.  [cited 2023 Aug 17]. NIH-Afrigen Agreement Will Help WHO’s Fight Against Pandemics. Available from: https://www.citizen.org/news/nih-afrigen-agreement-will-help-whos-fight-against-pandemics/.</Citation></Reference><Reference><Citation>Halabi S, Gostin LO, Aneja K, Nardi F, Gottschalk K, Monahan J. The Coalition for Epidemic Preparedness Innovations (CEPI) and the Partnerships of Equitable Vaccine Access. Journal of Law, Medicine &amp; Ethics. 2023. Jun;51(2):234–46. doi: 10.1017/jme.2023.85</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/jme.2023.85</ArticleId><ArticleId IdType="pmc">PMC10881267</ArticleId><ArticleId IdType="pubmed">37655558</ArticleId></ArticleIdList></Reference><Reference><Citation>Price WN, Rai AK, Minssen T. Knowledge transfer for large-scale vaccine manufacturing. Science. 2020. Aug 21;369(6506):912–4. doi: 10.1126/science.abc9588</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc9588</ArticleId><ArticleId IdType="pubmed">32792464</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy V. Capitalizing a Cure: How Finance Controls the Price and Value of Medicines. 2023. 245 p.</Citation></Reference><Reference><Citation>Comanor WS, Scherer FM. Mergers and innovation in the pharmaceutical industry. Journal of Health Economics. 2013. Jan 1;32(1):106–13. doi: 10.1016/j.jhealeco.2012.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhealeco.2012.09.006</ArticleId><ArticleId IdType="pubmed">23220457</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold ER. The fall of the innovation empire and its possible rise through open science. Research Policy. 2021. Jun 1;50(5):104226. doi: 10.1016/j.respol.2021.104226</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.respol.2021.104226</ArticleId><ArticleId IdType="pmc">PMC8024784</ArticleId><ArticleId IdType="pubmed">34083844</ArticleId></ArticleIdList></Reference><Reference><Citation>Skipworth W.
Danaher Lowers Price Of Tuberculosis Test After Pressure Campaign.
Forbes [Internet]. 2023. 
Sep
19 [cited 2023 Oct 23]; Available from: https://www.forbes.com/sites/willskipworth/2023/09/19/danaher-lowers-price-of-tuberculosis-test-after-pressure-campaign/.</Citation></Reference><Reference><Citation>Gotham D, McKenna L, Deborggraeve S, Madoori S, Branigan D. Public investments in the development of GeneXpert molecular diagnostic technology. PLOS ONE. 2021. Aug 31;16(8):e0256883. doi: 10.1371/journal.pone.0256883</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256883</ArticleId><ArticleId IdType="pmc">PMC8407584</ArticleId><ArticleId IdType="pubmed">34464413</ArticleId></ArticleIdList></Reference><Reference><Citation>Driouich JS, Bernadin O, Touret F, de Lamballerie X, Nougairède A. Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model. Antiviral Res. 2023. Jul;215:105638. doi: 10.1016/j.antiviral.2023.105638</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2023.105638</ArticleId><ArticleId IdType="pmc">PMC10191698</ArticleId><ArticleId IdType="pubmed">37207822</ArticleId></ArticleIdList></Reference><Reference><Citation>Moniotte N.
Afrigen Biologics and Dillico sign CRADA to advance mRNA manufacturing solutions [Internet].
DILLICO—Unleash the full potential of mRNA. [cited 2023. 
Oct
24]. Available from: https://dillico.com/afrigen-biologics-and-dillico-sign-crada-to-advance-mrna-manufacturing-solutions/.</Citation></Reference><Reference><Citation>Abi. Development of First African-Owned COVID-19 Vaccine [Internet]. Quantoom. 2022.  [cited 2023 Oct 24]. Available from: https://quantoom.com/new-agreement-paves-way-for-development-of-first-african-owned-covid-19-vaccine/.</Citation></Reference><Reference><Citation>Editor. Afrigen teams up with Univercells and eTheRNA to develop first African-owned COVID-19 vaccine | HealthCare Middle East &amp; Africa Magazine [Internet]. 2022.  [cited 2023 Oct 24]. Available from: https://www.healthcaremea.com/afrigen-teams-up-with-univercells-and-etherna-to-develop-first-african-owned-covid-19-vaccine/.</Citation></Reference><Reference><Citation>Victoria And South Africa To Partner On mRNA Vaccines | Premier of Victoria;  [Internet]. [cited 2023 Oct 24]. Available from: http://www.premier.vic.gov.au/victoria-and-south-africa-partner-mrna-vaccines.</Citation></Reference><Reference><Citation>Holly. Introducing Quantoom Biosciences—Medicines &amp; Autonomy Bioproduction [Internet]. Quantoom. 2021.  [cited 2023 Nov 28]. Available from: https://quantoom.com/ntroducing-quantoom-biosciences-a-univercells-company-with-the-mission-to-improve-access-to-essential-medicines-and-autonomy-in-bioproduction-through-innovation/.</Citation></Reference><Reference><Citation>Epstein GA. Financialization and the World Economy. Edward Elgar Publishing; 2005. 472 p.</Citation></Reference><Reference><Citation>Busfield J. Documenting the financialisation of the pharmaceutical industry. Social Science &amp; Medicine. 2020. Aug 1;258:113096. doi: 10.1016/j.socscimed.2020.113096</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113096</ArticleId><ArticleId IdType="pubmed">32563788</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulum Ö, Lazonick W. Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry. International Journal of Political Economy. 2018. Oct 2;47(3–4):281–316.</Citation></Reference><Reference><Citation>Benavides X. Private Equity Firms and the Financialization of Digital Clinical Trials [Internet]. Rochester, NY; 2023 [cited 2024 Jun 2]. Available from: https://papers.ssrn.com/abstract=4565316.</Citation></Reference><Reference><Citation>Medicines Patent Pool. Governance &amp; Team—MPP [Internet]. 2020.  [cited 2024 May 17]. Available from: https://medicinespatentpool.org/who-we-are/governance-teams.</Citation></Reference><Reference><Citation>Cassier M, Sinding C. ‘Patenting in the public interest:’ administration of insulin patents by the University of Toronto. History and Technology. 2008;24(2):153–71.</Citation></Reference><Reference><Citation>Schultz J, Urban JM. Protecting Open Innovation: The Defensive Patent License as a New Approach to Patent Threats, Transaction Costs, and Tactical Disarmament. Harv J L &amp; Tech. 2012 2013;26(1):1–68.</Citation></Reference><Reference><Citation>MPP. Annual Reports—MPP [Internet]. 2020.  [cited 2024 Jan 15]. Available from: https://medicinespatentpool.org/who-we-are/annual-reports.</Citation></Reference><Reference><Citation>News ABC. ABC News. [cited 2023. 
Nov
24]. Gates Foundation funding $40 million effort to help develop mRNA vaccines in Africa in coming years. Available from: https://abcnews.go.com/Health/wireStory/gates-foundation-funding-40-million-effort-develop-mrna-103827236.</Citation></Reference><Reference><Citation>CEPI. CEPI. 2023.  [cited 2024 Jan 5]. CEPI and Bio Farma partnership boosts rapid response vaccine manufacturing for the Global South. Available from: https://cepi.net/news_cepi/cepi-and-bio-farma-partnership-boosts-rapid-response-vaccine-manufacturing-for-the-global-south/.</Citation></Reference><Reference><Citation>Wenham C. Creating more and more new institutions may not make the world safer from pandemics. PLOS Global Public Health. 2023. May 17;3(5):e0001921. doi: 10.1371/journal.pgph.0001921</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0001921</ArticleId><ArticleId IdType="pmc">PMC10191324</ArticleId><ArticleId IdType="pubmed">37195920</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzscheiter A. Coping with Institutional Fragmentation? Competition and Convergence between Boundary Organizations in the Global Response to Polio. Review of Policy Research. 2017;34(6):767–89.</Citation></Reference><Reference><Citation>Storeng KT, de Bengy Puyvallée A, Stein F. COVAX and the rise of the ‘super public private partnership’ for global health. Global Public Health. 2023. Jan 2;18(1):1987502. doi: 10.1080/17441692.2021.1987502</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17441692.2021.1987502</ArticleId><ArticleId IdType="pubmed">34686103</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoey L. No Such Thing as a Free Gift: The Gates Foundation and the Price of Philanthropy. Reprint edition. London New York: Verso; 2016. 304 p.</Citation></Reference><Reference><Citation>MPP. Medicines Patent Pool. 2023.  [cited 2024 Jan 15]. MPP Strategy 2023–2025—MPP. Available from: https://medicinespatentpool.org/news-publications-post/mpp-strategy-2023-2025.</Citation></Reference><Reference><Citation>Trouiller P, Torreele E, Olliaro P, White N, Foster S, Wirth D, et al.. Drugs for neglected diseases: a failure of the market and a public health failure? Tropical Medicine &amp; International Health. 2001;6(11):945–51. doi: 10.1046/j.1365-3156.2001.00803.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-3156.2001.00803.x</ArticleId><ArticleId IdType="pubmed">11703850</ArticleId></ArticleIdList></Reference><Reference><Citation>Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002. Jun 22;359(9324):2188–94. doi: 10.1016/S0140-6736(02)09096-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)09096-7</ArticleId><ArticleId IdType="pubmed">12090998</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamey G, Torreele E. The world’s most neglected diseases. BMJ. 2002. Jul 27;325(7357):176–7. doi: 10.1136/bmj.325.7357.176</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.325.7357.176</ArticleId><ArticleId IdType="pmc">PMC1123710</ArticleId><ArticleId IdType="pubmed">12142292</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab T. The Bill Gates Problem: Reckoning with the Myth of the Good Billionaire. Metropolitan Books; 2023. 496 p.</Citation></Reference><Reference><Citation>Schwab T. Covid-19, trust, and Wellcome: how charity’s pharma investments overlap with its research efforts. BMJ. 2021. Mar 3;372:n556. doi: 10.1136/bmj.n556</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n556</ArticleId><ArticleId IdType="pubmed">33658184</ArticleId></ArticleIdList></Reference><Reference><Citation>Torreele E, McNab C, Adeyi O, Bonnell R, Dhaliwal M, Hassan F, et al.. It is time for ambitious, transformational change to the epidemic countermeasures ecosystem. The Lancet. 2023. Mar 25;401(10381):978–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">36924776</ArticleId></ArticleIdList></Reference><Reference><Citation>MPP.
Pioneering Partnerships: The mRNA Technology Transfer Programme Inks Groundbreaking mRNA Vaccine R&amp;D Consortia at Singapore Scientific Colloquium—MPP [Internet].
2024.  [cited 2024 Mar 28]. Available from: https://medicinespatentpool.org/news-publications-post/pioneering-partnerships-the-mrna-technology-transfer-programme-inks-groundbreaking-mrna-vaccine-rd-consortia-at-singapore-scientific-colloquium.</Citation></Reference><Reference><Citation>Medicines Patent Pool.
Pioneering Partnerships: The mRNA Technology Transfer Programme Inks Groundbreaking mRNA Vaccine R&amp;D Consortia at Singapore Scientific Colloquium—MPP [Internet].
2024.  [cited 2024 May 17]. Available from: https://medicinespatentpool.org/news-publications-post/pioneering-partnerships-the-mrna-technology-transfer-programme-inks-groundbreaking-mrna-vaccine-rd-consortia-at-singapore-scientific-colloquium.</Citation></Reference><Reference><Citation>TIME [Internet]. 2024.  [cited 2024 May 19]. Charles Gore. Available from: https://time.com/6962885/charles-gore/.</Citation></Reference><Reference><Citation>Tucker TJ, Makgoba MW. Public-Private Partnerships and Scientific Imperialism. Science. 2008. May 23;320(5879):1016–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18497279</ArticleId></ArticleIdList></Reference><Reference><Citation>Paremoer L, Pollock A. “A passion to change the landscape and drive a renaissance”: The mRNA Hub at Afrigen as decolonial aspiration. Front Public Health. 2022. Nov 28;10:1065993. doi: 10.3389/fpubh.2022.1065993</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.1065993</ArticleId><ArticleId IdType="pmc">PMC9742483</ArticleId><ArticleId IdType="pubmed">36518568</ArticleId></ArticleIdList></Reference><Reference><Citation>PAHO. Landmark report charts route for reorienting economies to deliver health for all—PAHO/WHO |
Pan American Health Organization;  [Internet]. 2023.  [cited 2024 May 19]. Available from: https://www.paho.org/en/news/24-5-2023-landmark-report-charts-route-reorienting-economies-deliver-health-all.</Citation></Reference><Reference><Citation>Mazzucato M, Li HL, Darzi A. Is it time to nationalise the pharmaceutical industry? BMJ. 2020. Mar 4;368:m769. doi: 10.1136/bmj.m769</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m769</ArticleId><ArticleId IdType="pubmed">32132003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapczynski A, Ramachandran R, Morten C. How Not to Do Industrial Policy.
Boston Review [Internet]. 2023. 
Oct
2 [cited 2024 May 17]; Available from: https://www.bostonreview.net/articles/how-not-to-do-industrial-policy/.</Citation></Reference><Reference><Citation>Kapczynski A, Michaels J. Administering a Democratic Industrial Policy [Internet]. Rochester, NY; 2024 [cited 2024 Jun 2]. Available from: https://papers.ssrn.com/abstract=4711216.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>